

# PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
Name	Execution Date
Ambrilia Biopharma Inc.	07/16/2009
<b>RECEIVING PARTY DATA</b>	
Name:	Kotinos Pharmaceuticals Inc.
Street Address:	666 Third Avenue
Internal Address:	Chrysler Center, 25th Floor
City:	New York
State/Country:	NEW YORK
Postal Code:	10017
<b>PROPERTY NUMBERS Total: 5</b>	
Property Type	Number
Patent Number:	7053058
Application Number:	11240937
Application Number:	11792000
Application Number:	11807589
Application Number:	11628392
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(617)542-2241
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	617-542-6000
Email:	jloebach@mintz.com
Correspondent Name:	Jennifer L. Loebach
Address Line 1:	One Financial Center
Address Line 2:	Mintz Levin
Address Line 4:	Boston, MASSACHUSETTS 02111
ATTORNEY DOCKET NUMBER:	39783-500

OP \$200.00 7053058

**500925640**

**PATENT**  
**REEL: 023032 FRAME: 0322**

NAME OF SUBMITTER:

Jennifer L. Loebach

Total Attachments: 4

source=39783500Assignment#page1.tif

source=39783500Assignment#page2.tif

source=39783500Assignment#page3.tif

source=39783500Assignment#page4.tif

## ASSIGNMENT OF PATENTS

WHEREAS, Ambrilia Biopharma Inc. (hereafter "Assignor"), a company incorporated under the laws of Canada, having its principal place of business at 1000, Chemin du Golf, Verdun, QC Canada H3E 1H4, is the sole and exclusive owner of all right, title and interest in and to the Patents and Patent Applications set forth on Schedule A attached hereto (hereafter "Patents and Patent Applications"); and


WHEREAS, Kotinos Pharmaceuticals Inc. (hereafter "Assignee"), a Delaware corporation having a principal place of business at Chrysler Center, 25<sup>th</sup> Floor, 666 Third Avenue, New York, NY, is desirous of acquiring the entire right, title and interest in and to the Patents and Patent Applications.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, BE IT KNOWN, that for the consideration of the sum of one (1) United States dollar and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred and conveyed and by these presents does hereby sell, assign, transfer and convey, unto said Assignee, its successors and assigns, the entire right, title and interest in and to the Patents and Patent Applications and all divisions, continuations, continuations-in-part and renewals thereof, and all Patents which may be granted thereon and all reissues, re-examinations and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for an invention described in any of the foregoing applications in any country or countries, together with the right to file such applications and the right to claim for the same the priority rights derived from the Patents and Patent Applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries and all extensions, renewals and reissues thereof; together with all claims for damages by reason of past infringement, with the right to sue for, and collect the same for the use of Assignee, its successors and assigns.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

Assignor hereby covenants and agrees that it has full right to convey the entire interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict herewith.

This assignment and the rights and obligations hereunder shall be construed in accordance with and governed by the internal law of the State of Delaware, USA without giving



effect to the conflict of law principles thereof, and the parties hereto hereby submit to the non-exclusive jurisdiction of the Courts in the State of Delaware, USA.


This assignment is effective as of this 16th day of July, 2009.


[The remainder of this page is intentionally left blank.]

A handwritten signature, possibly reading "Ch", is located in the bottom right area of the page.

IN WITNESS WHEREOF, Assignor has caused these presents to be signed by a duly authorized officer.


AMBRILIA BIOPHARMA INC., Assignor

By:   
Name: Monique Létourneau  
Title: Executive Vice-President, Finance & Chief Financial Officer


By:   
Name: Richard La Rue  
Title: Vice-President, Legal Affairs, Human Resources & Corporate Secretary

Witnesses:


Signature:

  
Name BRIAN DAVIES

Signature:


  
Name: Katherine Bontar

Kotinos Pharmaceuticals Inc., Assignee


By:   
Name: NICHOLAS G. BACOPOULOS  
Title: chairman and CEO

Witnesses:

Signature:

  
Name GREGORY SIWAPANKO

Signature:

  
Name: Mosafos ANDREAS.3

**SCHEDULE A**  
**to Patent Assignment**

<b>Ambrilia Reference</b>	<b>Title: Pharmaceutical Preparations for Inhibiting Tumors</b>	<b>Country</b>	<b>Application, Patent Numbers</b>
030-US-03	Priority Date: October 16, 2000	US	09/977,406, 7,053,058,
030-US-04	Inventors: Seema Garde; Chandra Panchal; Madhulika Baijal-Gupta; Jennifer Fraser and Salam Kadhim	US	11/240,937
030-CA-03		CA	2359650
030-EP-03	Assignee: Ambrilia Biopharma Inc.	EP	01981990.3, EP1326981
030-AU-03		AU	2002213691
030-JP-03		JP	2002-5636061, JP2004510833
059-WO-03	<b>Title: Laminin Receptor Binding Molecule</b>	WO, CA	WO06058431, CA2005/001831
059-CA-03	Priority Date: June 1, 2005	CA	2591301
059-US-03	Inventors: Borhane Annabi; Chandra J. Panchal; Jinzi Jason Wu; Richard Béliveau; Marcia Ruiz; Seema Garde and Mounia Bouzeghrane	US	11/792,000
059-EP-03	Assignee: Ambrilia Biopharma Inc.	EP	5815992.2, EP1833501
057-US-05	<b>Title: Method and Composition for Treating Angiogenesis and for Preventing Cancer Progression and Metastasis comprising a PSP94 Family Member</b> Priority Date: September 26, 2003 Inventors: Chandra J. Panchal; Jinzi Jason Wu; Richard Béliveau; Marcia Ruiz; Borhane Annabi; Sylvie Lamy; Mounia Bouzeghrane; Luc Daigneault; Robert Hawkins Assignee: Ambrilia Biopharma Inc.	US	11/807,589
057-US-06	<b>Title: Method and Composition for Treating Angiogenesis and for Preventing Cancer Progression and Metastasis</b>	US	11/628,392
057-CA-03	Priority Date: January 6, 2004 Inventors: Chandra J. Panchal; Jinzi Jason Wu; Richard Béliveau; Marcia Ruiz; Seema Garde; ; Borhane Annabi; Sylvie Lamy; Mounia Bouzeghrane; Luc Daigneault; Robert Hawkins;	CA	2567901
057-AU-01	Assignee: Ambrilia Biopharma Inc.	AU	2005250059
057-CA-02	<b>Title: Regulation Of Matrix Metalloproteinases By Psp94 Family Members</b> Priority Date: September 26, 2003 Inventors: Chandra J. Panchal; Luc Daigneault; Robert Hawkins; Marcia Ruiz; Seema Garde Assignee: Ambrilia Biopharma Inc.	CA	2545639

